Clinical trials
Completed Phase 2 Hepatitis B, Chronic trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
75 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 3 |
| 2003 | 3 |
| 2004 | 2 |
| 2006 | 3 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 3 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 5 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 4 |
| 2019 | 3 |
| 2020 | 10 |
| 2021 | 8 |
| 2022 | 5 |
| 2023 | 3 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 75 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Gilead Sciences | 13 |
| Bristol-Myers Squibb | 4 |
| GlaxoSmithKline | 4 |
| Hoffmann-La Roche | 4 |
| Chongqing Jiachen Biotechnology Ltd. | 3 |
| Janssen Research & Development, LLC | 3 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 3 |
| Arbutus Biopharma Corporation | 2 |
| Ascletis Pharmaceuticals Co., Ltd. | 2 |
| Assembly Biosciences | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hepatitis B, Chronic | 75 |
| Hepatitis B | 19 |
| Hepatitis | 8 |
| Carcinoma, Hepatocellular | 1 |
| Communicable Diseases | 1 |
| Fibrosis | 1 |
| Glomerulonephritis | 1 |
| HIV Infections | 1 |
| Hepatitis D | 1 |
| Hepatitis D, Chronic | 1 |
Trials
Showing 1 to 25 of 75. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.